609P - First results from the phase I dual rectal angiogenesis MEK inhibition radiotherapy (DREAMTHERAPY) trial in locally advanced rectal cancer

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Clinical research
Surgical oncology
Colon and Rectal Cancer
Basic Scientific Principles
Radiation oncology
Presenter Francisca Marti Marti
Authors F.E. Marti Marti1, A. Backen2, A.G. Renehan3, P. Manoharan4, A. Jackson5, V. Misra6, O. Ataman7, G.C. Jayson8, C. Dive2, M. Saunders6
  • 1Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/UK
  • 2Clinical And Experimental Pharmacology, The Paterson Institue for Cancer Research, Manchester/UK
  • 3Surgery, The Christie Hospital NHS Foundation Trust and Paterson Institute for Cancer Research, Manchester/UK
  • 4Radiology, The Christie Hospital NHS Foundation Trust, Manchester/UK
  • 5Radiology, Wolfson Molecular Imaging Centre, Manchester/UK
  • 6Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester/UK
  • 7Rockit, Astra Zeneca, Alderley Park/UK
  • 8Medical Oncology, The Christie NHS Foundation Trust, GB-M20 4BX - Manchester/UK



Less than 15% of patients (pts) receiving pre-operative chemoradiation (CRT) for rectal cancer have a complete pathological response (pCR). We tested the hypothesis that the addition of cediranib (a VEGFR TKI) or selumetinib (a MEK inhibitor), in combination with CRT, increases the proportion of complete responders. A translational protocol was also developed to study potential predictive biomarkers.


This hypothesis was evaluated in a dual phase I design. The drugs are evaluated in parallel in an intertwined design: once a cohort of pts on cediranib completed treatment and during the toxicity assessment period, another cohort of pts was commenced on selumetinib at the next dose level. Alternating cohorts maximised the efficacy of their evaluation. The analysis here is for cediranib only. Pts received CRT (45Gy in 25#, capecitabine 825 mg/m2 twice daily for 35 days) in three cohorts with cediranib: 15 mg, 20 mg and 30 mg/once daily (OD). Dose escalation was done upon fulfilment of the safety criteria outlined in the protocol. Cediranib was commenced 10 days prior to the start of CRT and continued throughout. Pts were followed up until and then after surgery. Safety, RECIST and pathological data were collected. In addition, blood, tissue and DCE-MRIs were obtained at baseline, post-monotherapy, throughout and post CRT for the study of candidate biomarkers.


15 mg cohort: 3 pts were recruited. 2 pts had a pCR and the 3rd pt had a clinical complete response (cCR) not requiring surgery. 20 mg cohort: 3 pts were treated. 1 had a cCR and ypT3N0 on resection. The other 2 had partial responses on MRI with ypT3N0 and ypT3N2 pathologically. 30 mg cohort: 3 pts were recruited at this dose level. Two pts had a cCR and the other one is waiting restaging. There was one DLT in this cohort (Grade III lethargy). This cohort will be expanded to a maximum n = 6. As yet, all pts have had R0 resections and completed all planned treatment (except pt with DLT who did not complete capecitabine). cCR pts remain disease free and have not had surgery.


The addition of cediranib to pre-operative CRT is a well tolerated regimen. All pts have responded with 5 out of 8 evaluable pts (62.5%) having either a pCR (n = 2) or cCR (n = 3). Updated clinical data, proposed optimal dose and translational data will be available for presentation at the meeting.


F.E. Marti Marti: Dr Marti's research fellowship is funded in equal parts by Cancer Research UK and Astra Zeneca.

O. Ataman: Dr Ataman is an Astra Zeneca employee.

G.C. Jayson: AZ advisory boards and research funding.

M.P. Saunders: I have previously been a paid advisor on an AZ trial with AZD2171 (Horizon II). However, I have no conflicts on the use of this agent in the DREAMtherapy trial.

All other authors have declared no conflicts of interest.